United Patients Group

JANUARY 4, 2024

As we move forward into 2024 and beyond, the sector offers diverse paths beyond direct patient care. The growth stems from rising healthcare demand, facility expansion, and the imperative for efficient administration to maintain quality patient care. Adverse drug events (ADEs) affect approximately 7 per 100 hospitalized patients.

Research and Development 52

Research and Development Patients Data Policy 52

MJ Business Attorneys

JUNE 29, 2018

Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome. For five years Mr. Feldmann worked under the United States Drug Enforcement Division.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. “It also creates new opportunities for researchers, entrepreneurs, investors and pharmaceutical companies.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

DECEMBER 11, 2021

Families of patients in the most urgent need often have to resort to support from crowdfunding or from individual donors to keep their medicine going. And really patients having to crowdfund for private-prescribed medicine because they can’t get it on the NHS is just not right in this country.”. Read more at. Also see Labour List.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

SEPTEMBER 1, 2021

Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. Perform regulatory impact assessment of CMC relevant changes to ensure continuous compliance with applicable regulations.

Research and Development 105

Research and Development Supply Chain Compliance Compliance 105

Cannabis Law Report

SEPTEMBER 29, 2022

The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd. If you suspect non-compliance in relation to therapeutic goods, you can report illegal or questionable practices online to the TGA.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

MMJ Recs

FEBRUARY 3, 2024

In recent years, the landscape of medical marijuana laws has evolved, presenting new opportunities and challenges for patients, healthcare providers, and industry stakeholders. Understanding these regulations is crucial for patients, caregivers, and dispensaries alike to ensure compliance with the law.

Legislation 52

Legislation Law Marijuana Dispensary 52

Cannabis Law Report

AUGUST 29, 2021

The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners.”. 1 Source: Passport, Euromonitor International, Cannabis in Latin America, July 2021.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

NORML

JANUARY 11, 2019

Legislation is pending, Senate Bill 2134, to permit qualifying patients to cultivate personal use quantities of cannabis for therapeutic purposes. The measure would permit patients to grow up to nine cannabis plants in a locked, enclosed facility, and to possess up to three ounces of home-grown medical cannabis. NH resident?

Legislation 191

Legislation Decriminalization Hemp Patients 191

Cannabis Law Report

JANUARY 23, 2022

Claire gained substantial pharmaceutical experience from her work in the biotechnology industry before transferring to cannabis in 2017. a business management and regulatory consulting firm, she led numerous Licensed Producers in achieving regulatory compliance and streamlining business operations. “I Greenridez 2.0 Acquisitions Corp.

History 52

History Pharmaceutical Compliance Compliance 52

MMJ Recs

APRIL 1, 2024

Its non-addictive nature and minimal side effects make it an attractive alternative to conventional pharmaceuticals for many individuals seeking natural remedies. By promoting relaxation and reducing anxiety, CBD may help individuals achieve restful sleep without the need for pharmaceutical interventions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

DECEMBER 15, 2021

for authorized research purposes at competitive prices, and aims to help ease supply chain issues currently facing hundreds of pharmaceutical companies, research institutions, and nonprofits across the United States of American that cannot find psilocybin for authorized research purposes at an affordable price. About Mycrodose Therapeutics.

Supply Chain 52

Supply Chain Research and Development DEA Pharmaceutical 52

Veriheal

OCTOBER 13, 2020

Elevated levels of stress can even land these individuals in more discomfort, with IBD patients risking hospitalization due to inflammation. Factors such as diet and stress are known to aggravate IBD patients, but they do not cause it. . What is IBS? What is the Difference Between IBD and IBS?

Digestion 123

Digestion Treatment Conditions Research and Development 123

Cannabis Law Report

MARCH 29, 2022

Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. Prior to his work at Moderna, Mullette developed broad pharmaceutical expertise with Sanofi in a variety of management roles in the U.S., Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. He holds a B.S.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. However, challenges such as regulatory compliance costs and market saturation may affect the profitability of cannabis businesses.

Legalization 52

Legalization Access Programs Education 52

Cannabis Law Report

JULY 29, 2021

With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”.

Extraction 98

Extraction Supply Chain THC Research and Development 98

Cannabis Law Report

NOVEMBER 21, 2021

Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. Provide technical support and ensure compliance during the development and approval of products for all markets.

Research and Development 52

Research and Development Compliance Compliance Pharmaceutical 52

Cannabis Law Report

OCTOBER 2, 2021

We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency. Team leadership: mentor European study teams in overall regulatory strategy and compliance to enable future patient access expeditiously. Position Requirements.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 19, 2021

We are a new kind of pharmaceutical company that prioritizes public benefit over profit and is committed to sustainability, accountability, and transparency. Team leadership : mentor European study teams in overall regulatory strategy and compliance to enable future patient access expeditiously. Position Requirements.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

APRIL 29, 2022

The product range is being manufactured to meet the growing demand for high quality medical cannabis products across Europe and builds on Curaleaf International being the first company to register a THC cannabis extract Active Pharmaceutical Ingredient (“API”) in Italy.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Patients 52

Cannabis Law Report

DECEMBER 14, 2019

Prohibition Partners’ has also estimated that up to 1 per-cent of the UK population could qualify as medical cannabis patients by 2028. Initially, Farmako Limited will pursue the import of Bedrocan products from the Netherlands to the UK for end patient distribution. VANCOUVER, British Columbia, Dec.

Pharmaceutical 59

Pharmaceutical Chronic Pain Patients Epilepsy 59

Cannabis Law Report

OCTOBER 10, 2021

As a think tank we develop new ideas and concepts for providing medical cannabis to patients both in Germany and Europe. Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis. “Development by innovation” is not an empty promise but our daily work motivator.

Clinical Trials 52

Clinical Trials Therapy Medicine Policy 52

Cannabis Law Report

JANUARY 28, 2022

By Maciej Konarowski, President of the Polish Medical Cannabis Patients Association and founder of the Can advocare law firm, and Conor O’Brien, Analyst at Prohibition Partners. Newly released data show that Poland is home to over 9,261 patients legally accessing medical cannabis, making it one of the largest such populations in Europe.

Legislation 52

Legislation Pharmaceutical Agriculture Cultivation 52

Cannabis Law Report

MAY 9, 2022

The company is following in the footsteps of GW Pharmaceuticals, a trailblazer that developed the first cannabis-based medicine to be licensed in the UK in 2010, Sativex for multiple sclerosis, which costs about £2,000 a year. However, NHS prescribing of the mouth spray remains very limited and varies across the country.

Chronic Pain 52

Chronic Pain Epilepsy Oil Pharmaceutical 52

MMJ Recs

JANUARY 6, 2024

In recent years, the landscape of medical marijuana has evolved dramatically, offering patients a diverse array of products tailored to address a myriad of health conditions. Capsules and pills provide a familiar oral ingestion method, akin to traditional pharmaceuticals.

Chronic Pain 52

Chronic Pain Topical Marijuana Indica 52

Cannabis Law Report

JUNE 24, 2021

Luxembourg is scrambling to secure a new medical cannabis supplier after encountering delays of up to 60 days, leaving new patients empty-handed. Initially, Aurora supplied the medicines, a Canadian firm that was replaced in 2019 by Canopy Growth-Spectrum Pharmaceutics. Website Delano reports. Complementary therapy.

Medicine 104

Medicine Chronic Pain Treatment Patients 104

Cannabis Law Report

OCTOBER 13, 2019

We jest…… on the news of Aurora Cannabis and CTT Pharmaceutical announcing the launch of their sublingual cannabis wafers. Aurora Cannabis and CTT Pharmaceutical Announce Launch of Sublingual Cannabis Wafers. Dissolve Strips Now Available to Aurora’s Canadian Medical Patients. Here’s the press release.

Pharmaceutical 40

Pharmaceutical Patients Cannabinoids Access 40

Cannabis Law Report

AUGUST 17, 2021

Technology licensing should be on the radar for pharmaceutical companies offering drugs for respiratory diseases. Improving Patient Outcomes with Real-time Feedback via Smart Inhalers and Portable and Lightweight Oxygen Concentrators for Increasing Home-Based Therapy is a Key Growth Opportunity. The Strategic Imperative. Cognita Labs.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

Cannabis Law Report

JUNE 19, 2021

Rules Based On Patient Benefit. Better inter-governmental co-operation must be beneficial as long as those involved understand that cannabis is a plant and not a pharmaceutical product.”. Grow Our Own”. This can only help the development of a thriving cannabis industry with consequent job creation and government tax income.

Research and Development 105

Research and Development Cannabinoids Medicine Hemp 105

CannaTech

DECEMBER 15, 2019

Can you imagine a pain doctor giving a patient such alarming advice? Of course not, this would never happen in the majority of our healthcare system, but with cannabis, it’s different, the patient must figure it out on their own. The light switch has already turned on for many patients. It is 100% patient driven.

Microdosing 52

Microdosing Education Patients Medicine 52

Cannabis Law Report

SEPTEMBER 14, 2022

The cannabis-based treatment, Sativex, will now be available via NHS prescription in Scotland, to treat spasticity in MS patients. Although a limited number of people have been able to access it via the Peer Approved Clinical System (PACS) Tier 2 individual patient treatment request process.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

FEBRUARY 15, 2019

Under strict manufacturing and pharmaceutical standards, 400 grammes of Bedrocan cannabis and 400 grammes of Bedica grown by Dutch biopharmaceutical firm, Bedrocan, was imported by IPS Specials following prescriptions issued for chronic pain at a cost of £695 per private patient. (In It has 15 wholly owned subsidiary companies.

History 56

History Legalization Chronic Pain Pharmaceutical 56

Cannabis Law Report

JANUARY 24, 2022

Ed’s insights will be critical as we review all results and determine the most efficient next steps to bring these novel treatments to patients. I am excited to be to be joining Goldfinch Bio during this key period of growth and am eager to work closely with such a dedicated and patient-focused team.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

AUGUST 12, 2021

Since 2013, medicinal cannabis has been legalized in the Czech Republic due to the amendment to the Act on pharmaceuticals, otherwise known as Act No. With medical research indicating that using the plant provides significant medical benefits, the Czech Chamber of Deputies suggested a revision to the government’s Act on pharmaceuticals.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

OCTOBER 21, 2021

A new nationwide study commissioned by SICPA North America, a leading provider of regulatory compliance solutions, and conducted online by The Harris Poll among over 2,000 U.S. The Press release says. adults shows broad support for securely labeling cannabis products to verify their legitimacy and safety in the marketplace.

Safety 52

Safety Research and Development Compliance Compliance 52

Cannabis Law Report

JULY 31, 2021

In other words, the TAR believes that the pharmacist should continue to operate as he sees fit , awaiting the (criminal or administrative) dispute on the shipment or preparation of other pharmaceutical forms of cannabis, and then challenge it before the TAR “, or go to trial in case of criminal charges.

Pharmaceutical 105

Pharmaceutical Cannabis Patients Law 105